Last updated: May 5, 2026
Most cancer patients use some form of complementary therapy – yet their oncologists often have no idea. This communication gap is not just a minor oversight. It can affect treatment safety, drug interactions, and patient outcomes. Understanding why this disconnect exists, and how to bridge it, is essential for anyone navigating cancer care in 2026.
How Many Cancer Patients Actually Use Complementary Therapies Like Therapeutic Nutrition?
The majority of cancer patients use complementary therapies including therapeutic nutrition, dietary supplements, and specialized diets. A 2023 Healing Works Foundation survey found that 64% of cancer patients use at least one complementary therapy, while a multi-institutional analysis published in JCO Oncology Practice reported usage as high as 70.2% among cancer patients across NCI-designated cancer centers.
These figures represent a significant and growing segment of the cancer patient population. Nearly 50% of newly diagnosed cancer patients begin using dietary supplements after their diagnosis, according to a 2025 analysis published in a National Institutes of Health-indexed journal. Americans spent approximately $58 billion on dietary supplements in 2023 alone, reflecting how deeply ingrained these products are in health-seeking behavior.
Two independent datasets – one from a large survey and one from a peer-reviewed multi-institutional study in JCO Oncology Practice – converge on the same conclusion: complementary therapy use among cancer patients is not a fringe phenomenon. It is the norm.
What Types of Complementary Approaches Are Cancer Patients Using Most?
Cancer patients pursue a wide range of complementary approaches. The most common categories include nutrition counselling, specialized therapeutic diets, dietary supplements, botanical products, and mind-body practices such as meditation and yoga. An ASCO abstract noted that 26% of patients expressed specific interest in dietary approaches as part of their cancer care.
It is important to distinguish between therapeutic nutrition – evidence-informed, clinician-guided nutritional strategies tailored to a patient’s cancer type and treatment phase – and unregulated, self-directed supplement use. The National Center for Complementary and Integrative Health (NCCIH), a division of the NIH, classifies complementary health approaches into categories including natural products, mind-body practices, and nutritional interventions. Understanding these distinctions helps patients make informed decisions about what they add to their care plan.
Is Patient Interest in Complementary Cancer Therapies Growing?
Patient interest in complementary therapies is not only high but actively shaping healthcare expectations. The 2023 Healing Works Foundation survey found that 71% of cancer patients want their health systems to offer complementary therapies, and 55% would choose a healthcare provider offering more integrative options over one that does not. Additionally, 87% of patients surveyed believe complementary therapies are beneficial to their care.
These numbers signal a clear market and clinical demand. When more than half of patients say they would switch providers based on the availability of complementary services, cancer centers that ignore this trend risk losing patients. For individuals exploring options this summer between treatment cycles, these statistics underscore a meaningful shift toward integrative expectations in oncology care.
Why Don’t Cancer Patients Tell Their Oncologists About Complementary Therapies?
Cancer patients frequently conceal their complementary therapy use from their oncology teams. The JCO Oncology Practice multi-institutional analysis found that 27.1% of cancer patients who used complementary therapies did not disclose this to their oncologist. A systematic review published in Integrative Cancer Therapies documented nondisclosure rates as high as 70%, with 67% of cancer survivors stating they did not think it was important to discuss complementary approaches with their doctor.
This nondisclosure is not driven by deception. It reflects a systemic breakdown in communication between patients and their medical teams – a breakdown that leaves oncologists making treatment decisions with incomplete information.
Are Patients Afraid Their Oncologist Will Disapprove?
A 2023 scoping review published in The Oncologist identified three primary barriers that prevent patients from disclosing complementary therapy use: fear of physician disapproval, assumed provider disinterest, and a belief that complementary therapies are not clinically relevant enough to mention during an oncology visit.
These barriers are understandable. Many patients worry that admitting supplement or diet use will damage their relationship with their oncologist or lead to a dismissive response. This concern is valid but often unfounded – and it creates a cycle of silence that benefits no one. Patients deserve to feel safe discussing every aspect of their care without fear of judgment.
Do Patients Get Their Information From Sources Outside Oncology?
The JCO Oncology Practice study found that 83% of cancer patients heard about complementary therapies from nonmedical sources – including friends, family, social media, and online communities. The same study noted that patients who used complementary and alternative medicine trusted nonmedical sources more than they trusted their oncology team.
This information asymmetry creates what amounts to a parallel treatment track. Patients make decisions about supplements, diets, and botanicals based on recommendations their oncologists never see, review, or have the opportunity to evaluate against the patient’s specific treatment protocol. The oncologist plans care with incomplete data, and the patient navigates conflicting advice without a coordinating authority.
What Do Oncologists Actually Think About Complementary Therapies?
Oncologists generally acknowledge the potential of complementary therapies but significantly underestimate how many of their patients use them. The Healing Works Foundation survey revealed that oncologists estimate only 40% of their patients use complementary therapies – while actual usage stands at 64% or higher. This 24-percentage-point gap means oncologists are unaware of complementary therapy use in roughly one out of every four patients who uses them.
The belief gap extends further. As reported by the ASCO Post in 2023, 57% of oncologists believe complementary therapies are effective for managing treatment side effects, yet only 33% believe they improve overall survival. This split may cause oncologists to view complementary approaches as low-priority topics during limited consultation time.
Perhaps most striking is the perception mismatch reported by ecancer.org: “One-third of oncologists mistakenly think patients lack interest [in complementary therapies], while only 13% of patients cite lack of interest as a barrier.” Oncologists are overestimating patient indifference while underestimating patient engagement.
Why Is There a 24-Point Gap Between Patient Use and Oncologist Awareness?
Several structural factors drive this gap. Oncology consultations are time-constrained, often focused on test results, treatment response, and symptom management. Most oncology fellowship programs include minimal training in nutrition science or integrative medicine. There are no standardized intake questions at most cancer centers asking patients about complementary therapy use.
The following table summarizes the key perception mismatches between patients and oncologists:
| Metric | Patient Reality | Oncologist Perception |
|---|---|---|
| Complementary therapy usage rate | 64 – 70% | Estimated at 40% |
| Patients wanting health systems to offer complementary therapies | 71% | One-third of oncologists believe patients lack interest |
| Nondisclosure of complementary therapy use | 27 – 70% do not disclose | Most oncologists unaware of nondisclosure scale |
| Patient belief that complementary therapies are beneficial | 87% | 57% of oncologists agree (side effects only) |
When physicians do not ask and patients do not volunteer, the communication gap becomes self-reinforcing. Both sides assume the other is not interested, and critical health information falls through the cracks.
What Are the Real Risks When Oncologists Don’t Know About a Patient’s Nutrition Plan?
When oncologists lack information about a patient’s complementary therapy use, clinically significant risks emerge. The NCCIH states directly: “Herbal supplements may have side effects, and some may interact in harmful ways with drugs, including those used in cancer treatment.” These interactions can reduce chemotherapy efficacy, interfere with radiation therapy, or cause unexpected toxicities that complicate an already demanding treatment course.
The risk categories are well-documented in the medical literature. They include nutrient-drug interactions that alter how chemotherapy agents are metabolized, antioxidant supplements that may inadvertently protect tumor cells during radiation, botanicals that affect liver enzyme pathways critical to drug processing, and high-dose vitamins that can interfere with specific targeted therapies.
Can Dietary Supplements Interfere With Chemotherapy or Radiation?
Yes, certain dietary supplements have documented interactions with chemotherapy and radiation protocols. The 2025 analysis on integrating botanicals into oncology care emphasizes the need for rigorous clinical evidence review before combining any supplement with conventional cancer treatment. Specific examples include St. John’s Wort, which can reduce the blood levels of certain chemotherapy drugs, and high-dose antioxidants, which may counteract the oxidative mechanisms by which some cancer treatments destroy tumor cells.
The critical distinction is this: the risk does not come from using therapeutic nutrition to support cancer treatment. The risk comes from using it without the oncologist’s knowledge. When a medical team knows what a patient is taking, they can time supplements around treatment, adjust dosages, or recommend evidence-supported alternatives.
What Happens When Therapeutic Nutrition Is Used Without Medical Coordination?
Uncoordinated use of therapeutic nutrition can lead to several adverse scenarios:
- Drug interactions that reduce or amplify treatment effects without the oncologist’s ability to identify the cause
- Suboptimal treatment outcomes that may be attributed to treatment failure rather than supplement interference
- Erosion of patient trust when unexpected complications arise and the care team cannot explain them
- Missed opportunities to use evidence-based nutritional strategies that could genuinely support treatment tolerance and recovery
The solution is not to avoid therapeutic nutrition. In clinical practice, carefully coordinated nutritional interventions can support immune function, improve treatment tolerance, and help maintain quality of life. The solution is to ensure every member of the care team – oncologist, nutritionist, and complementary practitioner – is working from the same information.
How Can Patients Start the Conversation About Therapeutic Nutrition With Their Oncologist?
Patients can significantly increase the likelihood of productive disclosure by preparing for the conversation in advance. Research published in the Journal of Cancer Survivorship found that patient-centered communication elements measurably increased disclosure odds: physician knowledge of patient-as-person increased disclosure by 28% (OR=1.28), and active information exchange increased it by 27% (OR=1.27). Patients who feel known and heard by their oncologist are more likely to share what they are taking.
The practical implication is clear: patients should not wait to be asked. Initiating the conversation is an act of self-advocacy that protects treatment integrity and opens the door to better-coordinated care.
What Should Patients Bring to Their Next Oncology Appointment?
Preparation transforms a potentially awkward conversation into a productive clinical exchange. Patients should bring the following to their next appointment:
- A written list of all supplements, including brand names, dosages, and timing relative to meals and treatments
- The name and credentials of any nutritional practitioner, naturopath, or integrative medicine provider they are working with
- Specific questions about potential interactions between their supplements and their current treatment protocol
- A request for referral to integrative oncology services if the current care team does not include a nutritionist
Having this information documented eliminates reliance on memory during a stressful appointment and gives the oncologist concrete data to work with.
How Should Patients Choose Between Conflicting Advice From Different Providers?
The JCO Oncology Practice study documented that cancer patients who use complementary therapies tend to trust nonmedical sources more than their oncology team. This creates a genuine dilemma when advice conflicts. The answer is not to choose one source over another but to seek providers who communicate with each other.
Evidence-based integrative oncology creates a framework where conventional oncologists and complementary practitioners share information, align strategies, and coordinate timing. Patients should look for care environments where this integration is built into the treatment model – not environments where they must serve as the messenger between disconnected providers.
What Does Evidence-Based Integrative Cancer Care Actually Look Like?
Evidence-based integrative cancer care is a treatment model where therapeutic nutrition, mind-body practices, and other complementary approaches are coordinated components of the overall treatment plan rather than hidden additions managed by the patient alone. In this model, oncologists, nutritionists, and complementary practitioners share information, review evidence together, and align their recommendations with the patient’s specific cancer type and treatment phase.
The demand for this model is clear: 71% of cancer patients want their health systems to offer complementary therapies, and 55% would switch providers to access them. Forward-thinking cancer centers are responding by building multidisciplinary teams that include integrative nutrition as a standard service rather than an afterthought.
How Is Therapeutic Nutrition Different From Unguided Supplement Use?
Therapeutic nutrition is a clinician-supervised, evidence-informed nutritional intervention tailored to a patient’s cancer type, treatment phase, metabolic status, and individual health needs. It is designed, monitored, and adjusted by qualified practitioners who coordinate with the oncology team.
Unguided supplement use, by contrast, is typically self-directed based on information from nonmedical sources, purchased without clinical oversight, and used without the oncologist’s knowledge. The following table highlights the key differences:
| Characteristic | Therapeutic Nutrition | Unguided Supplement Use |
|---|---|---|
| Supervised by credentialed practitioner | Yes | Typically no |
| Tailored to cancer type and treatment phase | Yes | Rarely |
| Coordinated with oncology team | Yes | Often undisclosed |
| Evidence basis reviewed for interactions | Yes | Varies widely |
| Adjusted based on treatment response | Yes | No |
EuroMed Foundation of Arizona practices this distinction daily. Their nutritional guidance and dietary protocols are integrated directly into each patient’s cancer care plan, ensuring that every recommendation works alongside – not against – conventional treatment.
Why Are More Cancer Centers Adding Integrative Nutrition to Their Programs?
The convergence of patient demand and emerging clinical evidence is driving adoption. With 57% of oncologists already acknowledging that complementary therapies help manage treatment side effects, and 55% of patients willing to switch providers for more integrative options, cancer centers face both a clinical and competitive incentive to integrate nutrition services.
Centers that offer coordinated integrative nutrition position themselves to deliver safer care by closing the communication gap, improving patient satisfaction by meeting stated preferences, and achieving better treatment tolerance outcomes. This summer, as patients research options between treatment cycles, the availability of integrated nutritional support is increasingly becoming a deciding factor in where patients choose to receive care.
Frequently Asked Questions About Complementary Therapies and Cancer Treatment
Is It Safe to Use Nutritional Supplements During Cancer Treatment?
Some nutritional supplements are evidence-supported and safe under clinical supervision, while others carry documented interaction risks with cancer treatments. The NCCIH, a division of the National Institutes of Health, warns that herbal supplements can interact harmfully with cancer drugs. Safety depends not on avoiding all supplements but on using them under the guidance of practitioners who coordinate with the oncology team and review each product against the patient’s specific treatment protocol.
Should I Tell My Oncologist About Vitamins and Herbal Supplements I Take?
Yes, always disclose all vitamins, herbal supplements, and dietary changes to your oncologist. Research shows that 27 – 70% of cancer patients do not disclose complementary therapy use, creating risks that neither the patient nor the physician can manage in isolation. Studies consistently find that oncologists are more receptive to these conversations than patients assume. Knowing that 64 – 70% of fellow cancer patients are in the same situation may help normalize the conversation.
What Is the Difference Between Complementary and Alternative Cancer Treatment?
Complementary therapies are used alongside conventional cancer treatment – such as adding therapeutic nutrition to a chemotherapy regimen. Alternative therapies are used instead of conventional treatment. The NCCIH defines this distinction clearly in its guidance for cancer patients. Therapeutic nutrition at a holistic treatment center like EuroMed Foundation is complementary – designed to work with, not replace, oncology protocols.
Do Oncologists Receive Training in Nutrition and Complementary Medicine?
Most oncology training programs include minimal education in nutrition science or integrative medicine. This is a systemic gap, not a reflection of individual physician attitudes. The scoping review in The Oncologist and the systematic review in Integrative Cancer Therapies both document how this training deficit contributes to the communication breakdown. The growth of integrative oncology programs at major cancer centers is gradually addressing this gap, but patients should not assume their oncologist has expertise in nutritional supplementation.
How Can I Find a Cancer Treatment Center That Offers Integrative Nutrition?
Look for cancer treatment centers with multidisciplinary teams that include credentialed nutritionists or registered dietitians with oncology experience. Ask specifically about communication protocols between complementary and conventional providers. Verify that therapeutic nutrition recommendations are evidence-based, individualized, and adjusted throughout treatment. EuroMed Foundation in Arizona offers this model of coordinated, holistic cancer care where nutritional therapy is built into the treatment plan from the start.
Why Does Closing the Communication Gap Matter for Every Cancer Patient
The evidence is clear: the majority of cancer patients use complementary therapies including therapeutic nutrition, most oncologists underestimate this usage by a wide margin, and the resulting communication gap creates real clinical risks – from drug interactions to missed opportunities for evidence-based nutritional support. The solution is not for patients to stop pursuing therapeutic nutrition. The solution is to bring it into the open.
Every cancer patient deserves a care team where all providers communicate, where nutritional strategies are evaluated for safety and efficacy, and where no one has to choose between conventional treatment and complementary support. Closing this gap starts with two actions: patients disclosing what they take, and care teams creating environments where that disclosure is welcomed.
If you are navigating cancer treatment and want a care environment where therapeutic nutrition is coordinated – not concealed – EuroMed Foundation of Arizona is here to help. Reach out to learn how an integrative, evidence-informed approach to cancer care can support your treatment journey this summer and beyond.
Frequently Asked Questions
How many cancer patients use complementary therapies without telling their oncologist?
Between 27% and 70% of cancer patients who use complementary therapies do not disclose this to their oncologist. Research published in JCO Oncology Practice found a 27.1% nondisclosure rate, while a systematic review in Integrative Cancer Therapies documented rates as high as 70%. Common reasons include fear of physician disapproval, assumed provider disinterest, and a belief that supplements are not clinically relevant enough to mention.
Can dietary supplements interfere with chemotherapy or radiation treatment?
Yes, certain dietary supplements have documented interactions with chemotherapy and radiation protocols. For example, St. John’s Wort can reduce blood levels of certain chemotherapy drugs, and high-dose antioxidants may protect tumor cells during radiation. The National Center for Complementary and Integrative Health warns that herbal supplements can interact harmfully with cancer drugs. Safety depends on coordinating all supplement use with the oncology team.
Why do oncologists underestimate how many patients use complementary therapies?
Oncologists estimate that roughly 40% of their patients use complementary therapies, while actual usage ranges from 64% to 70% – a 24-point gap. Structural factors drive this disconnect, including time-constrained consultations, minimal nutrition training in oncology fellowships, and the absence of standardized intake questions about complementary therapy use at most cancer centers. One-third of oncologists also mistakenly believe patients lack interest in these approaches.
What should I bring to my oncology appointment to discuss supplements and nutrition?
Patients should bring a written list of all supplements including brand names, dosages, and timing relative to meals and treatments. Include the name and credentials of any nutritional or integrative medicine practitioner involved in care. Prepare specific questions about potential interactions with the current treatment protocol, and request a referral to integrative oncology services if the care team does not already include a nutritionist.
What is the difference between therapeutic nutrition and unguided supplement use?
Therapeutic nutrition is a clinician-supervised, evidence-informed nutritional intervention tailored to a patient’s cancer type, treatment phase, and metabolic status. It is coordinated with the oncology team and adjusted based on treatment response. Unguided supplement use is typically self-directed from nonmedical sources, purchased without clinical oversight, and often undisclosed to the oncologist – creating potential interaction risks.
How long does it take to integrate therapeutic nutrition into a cancer treatment plan?
Integration can begin at any point during treatment, though starting early allows the care team to establish baseline nutritional status and coordinate supplement timing around chemotherapy or radiation cycles. At centers with multidisciplinary teams, an initial nutritional assessment and protocol alignment with the oncology team can typically be completed within the first one to two appointments, with ongoing adjustments throughout treatment.
What results can cancer patients expect from coordinated integrative nutrition?
When therapeutic nutrition is properly coordinated with conventional cancer treatment, patients may experience improved treatment tolerance, better maintained immune function, and enhanced quality of life during and after therapy. Research shows 57% of oncologists acknowledge complementary therapies help manage treatment side effects. The key factor is coordination – nutritional strategies must be reviewed for safety and tailored to each patient’s specific protocol to deliver meaningful results.